Efficacy of zolmitriptan nasal spray in management of acute migraine

Ramesh Bhattacharyya, Debala Laha and P.K. Gangopadhyay

Department of Neurology, Calcutta National Medical College & Hospital, West Bengal

KEY WORDS
Migraine
Zolmitriptan
CGRP

ABSTRACT

Background: Migraine is a very common neurological disorder. Treatment of acute attack of migraine is difficult. Non specific treatment includes various analgesic preparations having incomplete pain relieving effect with lot of side effects. Specific treatment for acute migraine attacks includes triptans and ergotamines.

Purpose: The purpose of this study was to examine the efficacy of zolmitriptan nasal spray in management of acute migraine.

Methods: In the present investigation zolmitriptan nasal spray is administered to patients having acute migraine attack. Visual analogue score was done every hour for headache and other symptoms.

Results: Headache, photophobia, phonophobia, nausea and disability are relieved completely in 60%, 60%, 50%, 80%, 75% cases respectively and partially in 25%, 20%, 35%, 15%, 15% respectively. Mild side effects which occurred after treatment are well tolerated by 90% of patients.

Conclusion: Zolmitriptan nasal spray not only reduces headache in 85% but it also reduces other symptoms of migraine like photophobia, phonophobia, nausea and disabilities.

doi: 10.5214/ans.0972.7531.180406

KEY WORDS
Migraine
Zolmitriptan
CGRP

Introduction

Migraine is an episodic brain disorder that affects 15% of general population. It is one of the very common referral to neurology clinic, highly disabling, costly and difficult to treat. Two types of treatment are available of which one is the treatment of acute attack. Another is for prophylaxis. Non specific treatment for acute attack includes aspirin, paracetamol, naproxen, ibuprofen, tolfenamic acid with or without antiemetic agents. Many patients suffer from 2 or more migraine attacks per month. Taking non specific analgesic more than 10 days per month can also produce drug induced headache. Moreover such drugs can also produce gastrointestinal (GI) intolerance. Specific treatments for migraine include ergotamine and triptans. Ergotamine is known to have higher incidence of nausea than triptans, however, its overuse can produce dreadful headache besides various vascular problems.

Triptans are very effective in acute migraine attack. Their pharmacokinetic features are excellent. There are very few studies depicting efficacy, tolerability and side effects of zolmitriptan in acute migraine attack.

Methods

Our study group consisted of 137 migraine patients from Neurology out door of Calcutta National Medical College and Hospital. Migraine diagnosis was confirmed by neurology according to simplified diagnostic criteria established for migraine adapted from the Headache Classification Committee of the International Headache Society 2004.

Those patients suffering from more than 3 months and having 2 or more attacks per month were recruited for this study and their headache and other symptom severity were assessed by visual analogue scale.

Repeated attack of headache lasting 4-72 hour that have these features, normal physical examination and no other reasonable cause of headache. Ethical approval was obtained.

Demographic characteristic, symptoms incidence and number of attack per month before treatment of the study group are shown in table 1, 2, 3 respectively.

Those patients were excluded from the study that presented with hypertension ischemic heart disease, complicated migraine and multiple risk factors for coronary vascular disease.

Table 1: Demographic characteristics of study group

|                | Percentage |
|----------------|------------|
| Male           | 35 (27%)   |
| Female         | 95 (73%)   |
| Age            | 4-50 years |
| Family history of migraine | 91 (70%) |
| Migraine with aura | 26 (20%) |

Table 2: Profile of clinical symptoms

| Symptom         | Percentage |
|-----------------|------------|
| Photophobia     | 111 (86%)  |
| Phonophobia     | 104 (80%)  |
| Nausea / Vomiting| 117 (90%) |
| Disability      | 117 (90%)  |

Table 3: No. of migraine attacks per month

| No of attacks | Percentage |
|---------------|------------|
| 2             | 20%        |
| 3             | 18%        |
| 4             | 15%        |
| 5 or more     | 30%        |
pregnancy and nursing mothers. All patients were given prophylactic drugs if migraine attacks were more than 2 per month or episodes were disabling for more than 2 days. Zolmitriptan nasal spray was given within 6-8 hour of migraine attack when pain was moderate to severe headache. The dose was repeated after 2 hours if it was partially effective.

One spray is equivalent to 5 mg of zolmitriptan. Repeat VAS scoring was done every 1 hour and change of symptoms was analyzed. 2nd dose of nasal spray was given if there was partial improvement of headache. Maximum dose did not exceed 2 days/week. There were 7 patients that required withdrawal of drug due to high cost and side effects.

Results
Improvement of headache and other various symptoms associated with it including photophobia, phonophobia, nausea and disability were assessed and side effects recorded. Headache was found to be relieved completely in 60%, partially in 25%, photophobia completely in 60%, partially in 20%. Phonophobia was found to be relieved completely in 50%, partially in 35%. Nausea was found to be completely relieved in 80%, partially in 15%. Similarly, disability was found to be completely resolved in 75%, partially in 15%. In 80% of patient’s headache improved within one hour. Recurrence within 24 hours was up to 30%, rebound headache of up to 30% and consistency (no recurrence within 24 hours) in 60% cases. 2nd dose of zolmitriptan did not improve symptoms further. Side effects included flushed sensation in 30% cases. Sensation of chest pressure was seen in 10%, with paresthesia in 10% and dizziness and weakness up to 20% while 5% patients required withdrawal of drugs due to side effects. We did not find any significant difference in migraine presenting with aura or without aura.

Discussion
Trigemino vascular system has a prominent role in migraine attack. It has been reported that there is sterile inflammation due to release of neuropeptides like calcitonin gene related peptides (GRP Neurokin A and Substance P) that could be involved in the pathophysiology of migraine. Triptans exert their treatment effects through presynaptic inhibition of peripheral trigemino vascular neurons (5HT1). Blocking of the calcium gene related peptide (CGRP) and vasconstriction are also possible mechanism of action of Triptans. Many patients have severe digestive symptoms precluding oral drug intake and a formulation of intranasal triptan has shown good efficacy. There are a few studies comparing efficacy of different type of triptans. Almotriptan at 12.5 mg was found to be effective for menstrually related migraine producing 48.4% pain free state and 2-24 hr of sustained pain free state in most patients. Rizatriptan at 10 mg was found to be effective producing 51% pain relief rate for 2 hr and 22% pain freedom with a sustained pain relief rate of 38% as well as good tolerance.

Our study found that zolmitriptan nasal spray not only reduces headache (85%) but it also reduces other symptoms of migraine like photophobia, phonophobia, nausea and disability (80-90%) of patient and with mild side effects like unpleasant test, flushed sensation, chest pressure dizziness (10-30%). 2nd dose of zolmitriptan nasal spray was not found to improve headache and other symptoms much.

Limitations
This is not a double blind, randomized, controlled clinical trial. It is not a comparative study with other triptans. Comparing efficacy in gender and age groups has not been conducted here.

The articles complies with International Committee of Medical Journal editor’s uniform requirements for the manuscripts. Competing interests – None. Source of Funding – None

Received Date : 4 February 2012; Revised Date : 9 February 2012
Accepted Date : 13 February 2012

References
1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from American Migraine Study II. Headache 2001; 41: 646–657.
2. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000; 62: 509–525.
3. Headache classification Committee of the International Headache Society. 2004. The International Classification of Headache disorders (2nd edition), Cephalalgia 2004; 24: 1–60.
4. Ohnhaus EE, Adler R. Methodological problems in measurement of pain: a comparison between verbal rating scale and the visual analogue scale. Pain 1975; 1: 379–384.
5. Hijazo PJ, Hosobuchi Y, Lamb S. Headache may arise from perturbation of the brain. Headache 1987; 27: 416–420.
6. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol. 1984; 16: 157–168.
7. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. N Engl J Med. 2002; 346: 257–270.
8. Knight YE, Edvinsson L, Goadsby PJ. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of atorvastatin and CP122, 298. Neuropeptides 1999; 33: 41–46.
9. Djupesland PG, Docekal P, Ehler E et al. Intranasal sumatriptan powder delivered by novel breath-actuated bi-directional device for the acute treatment of migraine: a randomized, placebo controlled study. Cephalalgia 2010; 30: 932–942.
10. Ferrari MD, Roon RJ, Lipton RB, et al. Oral triptans (serotonin 5-HT1D agonists) in acute migraine treatment: a meta analysis of 53 trials. Lancet 2001; 358: 1669–1675.
11. Allais G, Bussone G, D’Andrea G et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double blind, placebo controlled study. Cephalalgia 2011; 31: 144–151.

Table 4: Symptoms relieved rate (%)

| Symptoms   | Complete | Partial | No |
|------------|----------|---------|----|
| Headache   | 60%      | 15%     | 25%|
| Photophobia| 60%      | 20%     | 20%|
| Phonophobia| 50%      | 35%     | 15%|
| Nausea     | 80%      | 15%     | 5% |
| Disability | 75%      | 15%     | 10%|

Table 5: Side effects of Zolmitriptan nasal spray

| Side effect                  | Percentage |
|------------------------------|------------|
| Flushed sensation            | 30%        |
| Sensation of chest pressure  | 10%        |
| Paresthesia                  | 10%        |
| Dizziness & weakness         | 20%        |
| Unpleasant taste             | 30%        |